• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Grifols pays $51m for minority stake in Access Biologicals

January 12, 2017 By Brad Perriello

Grifols acquires stake in Access BiologicalsGrifols (NSDQ:GRFS) said today that it paid $51 million for a 49% stake in Access Biologicals, in a deal that includes an option to acquire the rest of the business.

That option, for the remaining 51% share in Vista, Calif.-based Access, goes live in 2022, Grifols said. The agreement also includes a provision to supply Access with non-human-use biologicals, the Spanish company said.

“The purpose of this acquisition is to enhance the activity of the Bio Supplies Division,” formerly the raw materials division, Grifols said in a regulatory filing.

Founded in 2006, Access collects and manufactures biologicals to the in vitro diagnostics, biopharmaceutical, cell culture and diagnostic R&D markets. The company claims to be the only firm “to directly collect and process Human AB serum at FDA licensed facilities located within the U.S.,” according to its website. Access has 3 divisions: the Access Plasma donation center, which includes collection and donor recruitment; Access Biologicals, which offers processed plasma and serum manufacturing, sales and marketing; and Access Cell Culture, offering a line of human and animal sera. Access also runs Saturn Biomedical, a plasma- and blood-collection center in Indianapolis, touting it as “the largest and newest specialty donor center in the U.S.”

Barcelona-based Grifols went on a buying spree last year, starting with its $100 million acquisition of a 49% stake in plasma collector Interstate Blood Bank in April 2016 (that deal also included an option to buy for the remainder). The next month, Grifols put $50 million on a 20% stake in clinical diagnostic tech developer Singulex.

And last month Hologic (NSDQ:HOLX) agreed to deal its stake in the Procleix blood-screening business it runs with Grifols, for nearly $1.9 billion.

Last September the U.S. Justice Dept. closed its probe of Grifols‘ possible violations of the Foreign Corrupt Practices Act.

Filed Under: Diagnostics, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Access Biologicals, Grifols

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS